Skip to main content
. 2024 Sep 16;20(12):4922–4940. doi: 10.7150/ijbs.87829

Figure 4.

Figure 4

TRPC5 promotes the motility and filopodia formation in gastrointestinal cancer cells. (A) Schematic representation of the movement trajectory in MKN-45 and DLD-1 cells treated with ML-204 (8 μM). (B) Representative bright-field images of MKN-45 and DLD-1 cells after treatment with ML-204 (8 μM). Scale bar: 300 μm. (C) TRPC5 protein-protein interaction network based on the TRIP database. (D) Representative MYO10 immunofluorescence (IF) staining in MKN-45 and DLD-1 cells following treatment with ML-204 (2, 4, and 8 μM) (blue: nuclei, red: MYO10, green: F-actin). Scale bar: 20 μm. (E) Quantification of MYO10-positive filopodia in MKN-45 and DLD-1 cells treated with ML-204 (2, 4, and 8 μM). Data are expressed as means ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 (vs. DMSO group). (F, G) Immunoblot analysis of RhoA, Rac1/2/3, and CDC42 expression in MKN-45 and DLD-1 cells after ML-204 treatment (2, 4, and 8 μM). Data are expressed as means ± SD, *P < 0.05, **P < 0.01, ***P < 0.001 (vs. DMSO group). (H) Representative MYO10 IF staining in MKN-45 and DLD-1 cells in WT and TRPC5 knockout groups (blue: nuclei, red: MYO10, green: F-actin). Scale bar: 20 μm. (I) Quantification of MYO10-positive filopodia in WT and TRPC5 knockout MKN-45 and DLD-1 cells. Data are expressed as means ± SD, **P < 0.01 (vs. WT group).